[1]常　玉,刘江鑫,李文生.髓系肉瘤伴T细胞异常表达病例的临床特征、形态学、免疫表型及分子遗传学研究[J].现代检验医学杂志,2022,37(03):11-15.[doi:10.3969/j.issn.1671-7414.2022.03.003]
　CHANG Yu,LIU Jiang-xin,LI Wen-sheng.Clinical, Morphological, Immunophenotypic and Genetic Analysis of Myeloid Sarcoma with Abnormal T-cell Expression[J].Journal of Modern Laboratory Medicine,2022,37(03):11-15.[doi:10.3969/j.issn.1671-7414.2022.03.003]
点击复制

髓系肉瘤伴T细胞异常表达病例的临床特征、形态学、免疫表型及分子遗传学研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年03期
页码:
11-15
栏目:
论　著
出版日期:
2022-05-15

文章信息/Info

Title:
Clinical, Morphological, Immunophenotypic and Genetic Analysis of Myeloid Sarcoma with Abnormal T-cell Expression
文章编号:
1671-7414（2022）03-011-05
作者:
常　玉1; 刘江鑫1; 李文生2
（1. 西安医学院，西安 710068；2. 陕西省人民医院病理科，西安 710068)
Author(s):
CHANG Yu1;  LIU Jiang-xin1; LI Wen-sheng2
(1. Xi’an Medical University, Xi’an 710021, China; 2. Department of Pathology, Shaanxi Provincial People’s Hospital, Xi’an 710068, China)
关键词:
髓系肉瘤; T 淋巴细胞; 异常抗原表达
分类号:
R551；R392.11
DOI:
10.3969/j.issn.1671-7414.2022.03.003
文献标志码:
A
摘要:
目的　探讨髓系肉瘤（ myeloid sarcoma，MS）伴 T细胞异常表达病例的临床病理特征。方法　选取陕西省人民医院 2021年 8月 6日确诊的 1例髓系肉瘤，采用 HE染色、免疫组织化学和原位杂交 EBER检测，观察其组织学特征、免疫表型以及原位杂交 EBER结果，随访患者，并进行相关文献复习。结果　患者女性， 52岁，活检部位为右颈部淋巴结，镜下髓系肉瘤肿瘤细胞形态单一，幼稚，染色质细腻，核分裂像易见，散在不成熟嗜酸性粒细胞。免疫组织化学 CD43，髓过氧化物酶（ myeloperoxidase，MPO），CD56阳性； CD34及 CD7部分阳性； CD3，CD4，CD8，CD2， CD5，TdT，CD20，CD79a，CD19，PAX-5，Grb，TIA-1，MUM-1，CD10，ALK，CD117和 CD1a阴性， CD21未见 FDC网，Ki67指数约 60%。原位杂交 EBER阴性。结论　髓系肉瘤表达 T细胞表面标志罕见，诊断需要结合临床、形态、免疫表型及遗传学等综合分析判断，以避免误诊为其它淋巴造血来源肿瘤。
Abstract:
Objective　To investigate the clinicopathological features of myeloid sarcoma（MS） with abnormal T cell expression. Methods　A case of MS diagnosed in Shaanxi Provincial People’s Hospital on August 6,2021 was studied by HE staining, immunohistochemistry and EBER in situ hybridization, and reviewed related literature. Results　The female patient was 52 years old. Biopsy of right cervical lymph nodes was performed that the tumor cells of MS were simple and immature, with fine chromatin, obvious mitotic figures and scattered immature eosinophils. Immunohistochemistry showed that these tumor cells were positive for CD43, myeloperoxidase（MPO）and CD56,with partial expression of CD34 and CD7.These cells did not express CD3, CD4, CD8, CD2, CD5, TdT, CD20, CD79a, CD19, PAX-5, Grb, TIA-1, MUM-1, CD10, ALK, CD117 and CD1a. CD21 showed no FDC network.Ki67 index was about 60%.EBER in situ hybridization was negative. Conclusion　Myeloid sarcoma expressing T cell is rare, and the diagnosis should be combined with clinical, morphological, immunophenotypic and genetic analysis to avoid misdiagnosing as other lymphohematopoietic tumors.

参考文献/References:

[1] 肖红燕，虎明明，樊学敏．髓系肉瘤14 例临床病理探讨[J]. 宁夏医学杂志，2020，42(12):1132-1134. XIAO Hongyan，HU Mingming，FAN Xuemin. Clinical and pathological study of 14 cases of myeloid sarcoma [J]. Ningxia Medical Journal, 2020,42(12):1132-1134.
[2] 汤平，董振坤，郭荣，等.89 例髓系肉瘤临床特征 及预后因素分析[J]. 中华器官移植杂志，2021， 42(3):173-176. TANG Ping，DONG Zhenkun, GUO Rong, et al. Clinical features and prognostic factors of 89 cases of myeloid sarcoma [J]. Chinese Journal of Organ Transplantation, 2021,42(3):173-176.
[3] KAWAMOTO K, MIYOSHI H, YOSHIDA N, et al. Clinicopathological, cytogenetic, and prognostic analysis of 131 myeloid sarcoma patients[J]. The American Journal of Surgical Pathology, 2016, 40(11): 1473-1483.
[4] SAMBORSKA M, DERWICH K, SKALSKASADOWSKA J, et al. Myeloid sarcoma in children - diagnostic and therapeutic difficulties[J]. Contemporary Oncology (Poznan, Poland), 2016, 20(6): 444-448.
[5] WANG Xin, LI Wensheng, ZHENG Yan, et al. The progression of CD56+ myeloid sarcoma: A case report and literature review[J]. Oncology Letters, 2016, 11(5): 3091-3096.
[6] KASHOFER K, GORNICEC M, LIND K, et al. Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next Generation sequencing[J]. Leukemia & Lymphoma, 2018, 59(2): 501-504.
[7] DALLAND J C, MEYER R, KETTERLING R P, et al. Myeloid sarcoma with CBFB-MYH11 fusion [inv(16) or t(16;16)] prevails in the abdomen[J]. American Journal of Clinical Pathology, 2020, 153(3): 333-341.
[8] GAJENDRA S, GORE A R, SOOD N, et al. Dicentric (7;12)(p11;p11) in T/myeloid Mixed-Phenotype acute leukemia[J]. Turkish Journal of Haematology, 2021, 38(3): 239-241.
[9] PI Yubo, WANG Beining, WANG Lihong, et al. Polyserositis as a primary clinical manifestation of CD7+ acute myelogenous leukemia with myeloid sarcoma: A case report[J]. Medicine, 2020, 99(50): e23615.
[10] 李敏, 朱明霞, 田磊, 等. 系别不确定的造血细胞肿 瘤病理诊断与鉴别诊断要点[J]. 中华血液学杂志， 2021, 42(3):238-242. LI Min, ZHU Mingxia, TIAN Lei, et al. The pathological diagnosis and differential diagnosis of hematopoietic cell tumors of ambiguous lineage [J]. Chinese Journal of Hematology, 2021,42(3):238-242.
[11] 马小雯, 王梅芳, 陈剑芳, 等. 髓系肉瘤3 例并文献 复习[J]. 山西医科大学学报，2018，49(6):743-745. MA Xiaowen，WANG Meifang，CHEN Jianfang， et al. Myeloid sarcoma: 3 case reports and literature review [J]. Journal of Shanxi Medical University, 2018,49(6):743-745.
[12] CAMPIDELLI C, AGOSTINELLI C, STITSON R, et al. Myeloid sarcoma: extramedullary manifestation of myeloid disorders[J]. American Journal of Clinical Pathology, 2009, 132(3): 426-437.
[13] KAUR V, SWAMI A, ALAPAT D, et al. Clinical characteristics, molecular profile and outcomes of myeloid sarcoma: a single institution experience over 13 years[J]. Hematology (Amsterdam, Netherlands), 2018, 23(1): 17-24.

相似文献/References:

[1]周林颖,刘 兴,伍 勇,等.HIV/AIDS 患者并发EBV 和HCMV 感染临床免疫学特征及影响因素分析[J].现代检验医学杂志,2024,39(02):91.[doi:10.3969/j.issn.1671-7414.2024.02.017]
　ZHOU Linying,LIU Xing,WU Yong,et al.Clinical Immunological Characteristic and Influencing Factors Analysis of HIV/AIDS Patients Infected with EBV and HCMV[J].Journal of Modern Laboratory Medicine,2024,39(03):91.[doi:10.3969/j.issn.1671-7414.2024.02.017]

备注/Memo

备注/Memo:
基金项目：陕西省重点研发计划项目（2019SF-089)；陕西省人民医院领军人才项目（2021LJ-12）。
作者简介： 常玉（1995-），女，在读硕士，住院医师，研究方向：肿瘤病理，E-mail:851295605@qq.com。刘江鑫（1995-），女，在读硕士，住院医师，研究方向：肿瘤病理，E-mail:liujx@126.com，同为第一作者。
通讯作者：李文生（1968-），男，医学博士，主任医师，研究方向：肿瘤病理诊断及淋巴瘤病理研究，E-mail: liwensheng263@sohu.com。
更新日期/Last Update: 1900-01-01